[51] demonstrated that the activation of innate immune pathways contributes to adaptive resistance in FLT3/ITD AML, indicating that pathways outside of RTK signaling can contribute to adaptive resistance. The gene discussed is FLT3; the disease is acute myeloid leukemia.